|Awarded On||August 18, 2021|
|Title||Recruitment of First-Time, Tenure-Track Faculty Members|
|Award Mechanism||Recruitment of First-Time, Tenure-Track Faculty Members|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Edward Grow|
|Summary of Goals and Objectives||
The objective of this proposal is to define the role of a p53-dependent non-canonical DNA damage response and how its reactivation of transposable elements (TE) can be leveraged to stimulate effective immunotherapy in cancer. The premise we will investigate is that combining epigenetic modulation with stimulation of the p53-DUX4 axis will allow for TE reactivation and potent sensitization of cancer cells to immunotherapy.
Although checkpoint-based immune-therapy has yielded impressive clinical results, most patients do not respond likely because they exhibit poor basal tumor immunity. A deeper understanding of how to leverage...